Alzheimer's Disease

Are there any drugs available to treat Alzheimer's?

The U.S. Food and Drug Administration (FDA) has approved four drugs to treat AD. For people with mild or moderate AD, donepezil (Aricept®), rivastigmine (Exelon®), or galantamine (Razadyne®) may help maintain cognitive abilities and help control certain behavioral symptoms for a few months to a few years. Donepezil can be used for severe AD, too. Another drug, memantine (Namenda®), is used to treat moderate to severe AD. However, these drugs don’t stop or reverse AD and appear to help patients only for months to a few years.

Where can I find information about Alzheimer’s disease?

The NIA's Alzheimer's Disease Education and Referral (ADEAR) Center is the government's leading resource on Alzheimer's disease and can help answer many of your questions. The ADEAR Center offers information and publications for families, caregivers, and professionals on diagnosis, treatment, patient care, caregiver needs, long-term care, education and training, and research related to Alzheimer's disease. Staff members answer telephone, email, and written requests and make referrals to local and national resources.

Is there a way to prevent Alzheimer's disease?

Currently, there is no definitive evidence about what can prevent Alzheimer’s disease or age-related cognitive decline. What we do know is that a healthy lifestyle—one that includes a healthy diet, physical activity, appropriate weight, and no smoking—can lower the risk of certain chronic diseases and boost overall health and well-being. Scientists are very interested in the possibility that a healthy lifestyle might delay, slow down, or even prevent Alzheimer’s.

My family member has just been diagnosed with Alzheimer’s disease. What should I do?

Visit www.alzheimers.gov, the Federal government’s gateway to reliable, comprehensive information about Alzheimer’s disease from Federal, State, and private organizations.

Prevention of Alzheimer's Disease: Current Considerations

The 8th Leonard Berg Symposium will take place on September 28, 2012, at the Eric P. Newman Education Center on the campus of Washington University School of Medicine. This conference will focus on a prevention trial design including: challenges and opportunities. Some of the most active and distinguished researchers in this exciting area will be speaking.

Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention

The Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention was held May 14-15, 2012.

Webcast of the Summit is available here:

Transcripts:

What is the National Institute on Aging?

The NIA is one of the 27 Institutes and Centers at the National Institutes of Health (NIH).  The NIA leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. The Institute supports and conducts genetic, biological, clinical, behavioral, social, and economic research related to the aging process, diseases and conditions associated with aging, and other special problems and needs of older people. The NIA is the primary Federal agency for research on Alzheimer’s disease.

Subscribe to RSS - Alzheimer's Disease